This biggest success of Week 2 was attending a happy hour networking event completely sober. I headed there with a friend who was also doing Whole30, and we vowed to be each other's support system. We ordered seltzer waters together and proudly said no to the cheeseburger sliders and cheese board. Leaving the event, I felt empowered knowing I had it in me to refuse alcohol and fatty food, something I'd never tried before. Plus, I now knew I didn't have to use alcohol as a social crutch.
My favorite part of CFA are the people. Everyone that I workout with are so motivating, fun, and down to earth! The coaches, wow YALL ARE INCREDIBLE!! Always so helpful and encouraging! People always ask how I am able to go and workout at 5:30 or 6:30 in the morning every day? And it’s because I’m excited to see everyone!! Having a family like this is so amazing!
Originally, teams were awarded the "Affiliate Cup" for having the best overall score from the individual athletes that had come from the same CrossFit-affiliated gym. In 2009, the Games began having a separate set of events for affiliate teams and consisted of four to six athletes from the same gym. The next season, the format was finalized to teams of three men and three women. In the 2018 games, each team was changed to four members, two men and two women. In 2019, CrossFit removed the stipulation that team members had to be from the same affiliate. Teams are subject to a similar qualification process as the individuals.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”